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Abstract 
Introduction: 
HIV infection/AIDS is a global pandemic, with cases reported from 
virtually every country. Some studies have found a good correlation of Lipid 
profile and Body Mass Index (BMI) with advanced HIV infection.  
Materials and Methodology:   
In considering the above facts, a cross sectional study (using 50 PLHA 
and 50 controls) was conducted in Govt Kilpauk Medical College Hospital 
using various clinical and laboratory measures such as WHO clinical Staging, 
Anthropometry (BMI), lipid profile were done and they were compared with 
CD4 count of PLHA. Then it was analysed to check whether these parameters 
can be used as a surrogate marker for CD4 count to initiate ART and to monitor 
the therapy. 
Observations and results: 
In our study, good number of patients had a „high risk‟ triglyceride range. 
Very high risk‟ cholesterol level is significantly higher among cases. PLHA had 
significantly lower level of LDL. HDL level was low among female cases. 
There is no significant correlation between the CD4 count and the Levels 
of various parameters of lipid profiles. Apart from the intended correlation, we 
also attempted to correlate various other parameters and we came to a 
conclusion that WHO categories correlates with CD4 count. Gender and HDL 
correlates well in our study population 
Conclusions: 
Although the CD4 count is used as “gold standard” test, WHO staging 
can be used as a surrogate marker for CD4 count to initiate ART in resource 
limited settings. Lipid profile can never be used as surrogate for CD4 count. 
Keywords: 
 Patient living with HIV/AIDS(PLHA); CD4 count; Dyslipidemia; 
Cross section study; WHO categories; Lipid profile; Body Mass Index 
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INTRODUCTION 
HIV infection/AIDS is a global pandemic, with cases reported from 
virtually every country. At the end of 2007, 33.2 million individuals were living 
with HIV infection (range: 30.6–36.1 million) according to the Joint United 
Nations Programme on HIV/AIDS (UNAIDS). More than 95% of people living 
with HIV/AIDS reside in low and middle-income countries of which 50% are 
female, and 2.5 million are children <15 years. In 2007, there were an estimated 
2.5 million new cases of HIV infection worldwide, including 420,000 in 
children <15 years. In 2007, global AIDS deaths totalled 2.1 million (including 
330,000 children <15 years). HIV incidence likely peaked in the late 1990s at 
>3 million new infections per year. Recent reductions in global HIV incidence 
likely reflect natural trends in the pandemic as well as the results of prevention 
programs resulting in behaviour change. Although the AIDS epidemic was first 
recognized in the United States and shortly thereafter in Western Europe, it very 
likely began in sub-Saharan Africa, which has been particularly devastated by 
the epidemic. More than two-thirds of all people with HIV infection (about 22.5 
million) live in that region, even though sub-Saharan Africa is home to just 10–
11% of the world's population .Within the region, southern Africa is worst 
affected. In eight southern African countries, available sero prevalence data 
shows that >15% of the adult population aged 15–49 is HIV-infected. In Asia, 
an estimated 4.9 million people were living with HIV at the end of 2007, of 
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2which 3.6 million people are in South East Asia. In 2007, there were 2.4 
million people live with HIV/AIDS in India with an estimated adult HIV 
prevalence of 0.34%. The cost of combination ART has dropped in recent years 
as a result of generic medicines and differential pricing based on country need 
and ability to pay. The cost of diagnostic services to determine eligibility for 
treatment and to monitor treatment response has kept ART inaccessible to 
many, however. The US Department of Health and Human Services (DHHS) 
and the World Health Organization (WHO) recommend initiating ART therapy 
based on consideration of a patient‘s CD4 T-cell count when available. A CD4 
cell count requires expensive laboratory equipment and trained technicians, 
which are absent in many areas of high HIV prevalence. The cost of monitoring 
HIV therapy may become more prohibitive than the cost of the medications 
themselves. In December 2003, the WHO broadened the recommendations for 
initiation of ART when CD4 testing is unavailable to include WHO stage III or 
IV or WHO stage II in combination with a TLC 1200 cells/mm3. Many studies 
have evaluated the use of TLC as a surrogate marker for CD4+ cell count with 
mixed results. Some studies have found a good correlation but others have not. 
In addition to low Lymphocyte count, Anaemia, Thrombocytopenia, Lipid 
profile and Body Mass Index (BMI) have been associated with advanced HIV 
infection. 
In considering the above facts, a cross sectional study was conducted in Govt 
Kilpauk Medical College Hospital using various clinical and inexpensive 
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laboratory measures such as WHO clinical Staging, Anthropometry (BMI), lipid 
profile were done and compared with CD4 count. It is analysed that these 
parameters can be used as a surrogate marker for CD4 count to initiate ART and 
to monitor the therapy. 
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AIMS AND OBJECTIVES 
 
AIM OF THE STUDY: 
1. To study the prevalence of dyslipidemia in patient not started on 
Highly Active Anti-Retroviral Therapy. 
2. To analyse the Lipid profile, CD4 count results and to check whether 
they are correlated with each other. 
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Review of literature 
HIV disease – AIDS and related disorder 
AIDS was recognised first in US 1981 when CDC reported unexplained 
occurrence of P. carinii pneumonia in five homosexual men. Later it was 
recognised in injection drug user blood transfusion recipients 
1983  HIV was isolated 
1984  HIV was demonstrated to be the causative organism for AIDS 
1985  ELISA 
CDC categories persons on the basis of clinical conditions/ CD4 count. 
There are three clinical and three CD4 range categories. Therefore it is 
represented by a matrix of 9 mutually exclusive categories. 
 Using this system, any HIV individual with CD4 count<200/microliter 
has AIDS by defubutuib regardless of presence of symptoms/ opportunistic 
infection. Once patient lands in category B he cannot go back to category A 
clinical condition, even if the condition resolves. The same goes strongly true 
for category C clinical condition in relation to category B 
[1]
. 
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Category A 
 One / more of conditions in adolescent/ adult (>13 yrs.) with documented 
HIV infection 
 Asymptomatic HIV infection 
 Acute HIV infection with accompanying illness 
 Persistent generalised lymphadenopathy 
Category B 
 One/ more of following criteria in adolescent or adult 
1) Condition attributed to HIV infection/ are indicative of defect in 
cell mediated immunity 
2) Conditions are considered by physician to have a clinical course 
to require management that is complicated by HIV infection 
a. Bacillary angiomatosis 
b. Herpes zoster 
c. Candidiasis 
d. Listeriosis 
e. Pelvic inflammatory disease 
f. Peripheral neuropathy 
g. Constitutional Symptoms like fever/ diarrhoea >1 month 
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Category C 
 Conditions in AIDS Surveillance case definition 
a. Candidiasis of bronchi, trachea, Lungs 
b. Candidiasis of Oesophagus 
c. Cervical Cancer – invasive 
d. Extra pulmonary/ Disseminated coccidiodomycosis 
e. Extra pulmonary/ Chronic intestinal cryptococcosis 
f. CMV retinitis 
g. HSV chronic ulcer/ Bronchitis pneumonia/ Esophagitis 
h. Extra pulmonary/ Disseminated Histoplasmosis 
i. Chronic intestinal isospora 
j. Kaposi sarcoma 
k. Burkitt‘s lymphoma/ Lymphoma of brain 
l. Mycobacterium avium complex 
m. Mycobacterium tuberculosis 
n. Recurrent pneumonia 
o. Pneumocystis jiroveci 
p. Wasting syndrome due to HIV[2] 
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 A- Asymptomatic/ Primary 
HIV/ Persistent 
generalised 
Lymphadenopathy 
B- Symptomatic 
individual 
C- AIDS 
indicator 
condition 
CD4 T cell 
count >500 
A1 B1 C1 
CD4 T cell 
count 200 
– 499 
A2 B2 C2 
CD4 T cell 
count <200 
A3 B3 C3 
 
Etiologic agents  
Human disease retroviruses are 
1) HTLV-1        Transforming retrovirus 
2) HTLV-2 
3) HIV1            Cytopathic effects directly/ indirectly 
4) HIV2 
HIV1 (M,N,O,P) and HIV2(A,B,C,D,E,F,G) are from chimpanzees/ 
gorilla and sooty mangabeys respectively 
 AIDS pandemic is predominantly caused by HIV1 M group virus 
[3]
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Morphology 
  
 Icosahedral with numerous spikes made of gp120 and gp40 
          
Replication 
  Hall mark enzymes – Reverse transcriptase, integrase 
I) The glycoprotein gp120 binds to CD4 molecule, then gp120 molecule 
undergo a conformational change and bind to one of the two major co-
receptors CCR5/ CXCR5. 
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II) The glycoprotein gp120 then binds to DC sign(c-type lectin receptor 
in dendritic cell). 
III) The glycoprotein gp41 penetrates plasma membrane of target. 
IV) Pre-integration complex (RNA, Enzymes, Capsid coat) is released 
onto cytoplasm and reaches nucleus. 
V) Viral RNA  proviral HIV DNA. This stage is most vulnerable stage 
ApoBEC family of protein – inhibits viral replication by, 
a. ApoBEC bind viral genome with subsequent reverse transcripts 
accumulation. 
b. ApoBEC, through its deaminase activity causes hypermutation 
VI) Proviral HIV DNA integrates with human chromosome 
Transcription 
 
Translation 
  
   Protein 
 
Post translational modification 
 (Glycosylation/ phosphorylation, myristoylation and cleavage) 
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 Budding occurs through a specialised region in the host cell membrane 
(lipid bilayer) known as lipid rafts. Protease catalyses the cleavage of the gag-
pol precursor to yield the mature virion 
[4]
 
Genome: - 
[46]
 
3 genes codes importantly for the structural proteins, 
Gene ‗gag‘ – Protein that form core of virion (p24) 
Gene ‗pol‘ – Reverse Transcriptase, protease, integrase 
Gene ‗env‘ – envelop glycoprotein (gp120, gp4) 
6 other genes (tat, rev, nef, vif, vpr, vpu) which modifies host cell, thereby 
enhance the viral growth. HIV2 has vpx instead of vpu in HIV1 
 Circulating recombinant-forms are generated when an individual is 
injected by 2 subtypes that then recombine and create a virus with a selective 
advantage. 
[5]
 
Transmission:- 
I. SEXUAL TRANSMISSION –most common mode 
a) Factors  
a. Viral load 
b. STD 
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i. Ulcerative – Treponema pallidum, Hemophilus ducryei, 
HSV. 
ii. Nonulcerative – Neisseria gonorrhoea, Chlamydia 
trochamatis, Trichomonas vaginalis. 
b) URAI > Vaginal intercourse transmission, because of 
a. Direct inoculation into blood. 
b. Infecting langerhan cell in mucosa. 
c) Viral load <1700 transmission is very rare. Therefore initiation 
ART(Anti-Retroviral Therapy) reduces plasma viremia thereby 
reducing transmission 
d) Treatment of Sexually Transmitted Disease will prevent HIV 
transmission  
e) Circumcision is associated with a lower risk of HIV infection for 
heterosexual men 
a. Fore skin contains high density of Langerhan cells  
b. Micro trauma to foreskin and glans penis 
c. Moist environment under foreskin 
f) Oral contraceptive increase HIV transmission by affecting cervical 
mucosa 
II. TRANSMISSION BY BLOOD/ BLOOD PRODUCTS 
a) Blood/ blood product transfusion/ transplanted tissue 
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b) Sharing injection, paraphernalia such as needles, syringes, the water in 
which they are mixed 
c) Few cases of HIV transmission via semen used in artificial 
insemination and tissues/organs used in organ transplantation have 
also been documented, prior to those screening procedures. At present, 
donors of such tissues are pre-screened for HIV infection. 
In case of HIV-serodiscordant couples (HIV-infected male; HIV-
uninfected female) who have desire to conceive a child, assisted reproductive 
techniques like sperm-washing to minimize the risk of transmission of HIV 
have been employed successfully, with only one well-documented failure of 
seroconversion (i.e., becoming infected with HIV infection)  in the uninfected 
female partner, reported in 1990.
[6]
 
III. TRANSMISSION OF HIV IN OCCUPATIONALLY VULNERABLE 
PERSON: 
Procedures that place a health worker at potentially high risk of HIV 
transmission are  
a) Percutaneous sharp injuries (e.g., a needle stick or cut with a sharp 
object) or  
b) Contact of non-intact skin or mucous membrane (e.g., exposed skin 
that is abraded, diseased with dermatitis, or chapped) with blood, 
infected tissue, or other potentially risky body fluids. Large, meta 
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centric studies have shown that the risk of transmission of HIV 
infection following a skin puncture by needles or sharp things that 
were contaminated by blood from person who was documented with 
HIV infection is approximately about 0.3% and following a mucous 
membrane exposure is 0.09% if the injured and/or exposed health care 
worker was not treated with antiretroviral drugs within 24 hours.  
c) Transmission of HIV infection following non-intact skin exposure has 
also been documented, but the mean risk of transmission via this route 
has not been appropriately determined. 
The most attention attracting dramatic reports of transmission of HIV 
infection in health care setting was the transmission of HIV infection to 
8000–10,000 children in Romanian orphanages in 1980s. Other largest 
incidents happened in health care setting/hospitals were in Russia and 
Libya in late 1980s and late 1990s, respectively. Each of these above 
incidents attracted considerable global attention and was likely related to 
repeated use of contaminated needles and/or provision of blood products 
which is contaminated by HIV infection. 
[50] 
IV. MATERNAL-INFANT/ FOETAL TRANSMISSION: 
 HIV infection may be transmitted from infected mother to her foetus 
during her pregnancy, during parturition, or via breast feeding. This still 
remains an important modality of HIV transmission in certain developing/ 
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underdeveloped countries, where the ratio of infected women to infected men 
was about 1:1. Virological analyses of aborted embryo/ foetuses denote that 
HIV infection can be transmitted from mother to the foetus/ embryo during first 
or second trimesters of the pregnancy. Despite this fact, maternal transmission 
to the foetus most commonly occurs in the peri-partum/ perinatal period. Two 
significant studies done in Rwanda and the former Zaire demonstrated the fact 
that approximate proportions of mother-to-child transmissions were 23–30% 
before delivery, 50–65% during parturition, and 12–20% through breast-feeding 
in post-partum period. 
Short-duration prophylactic antiretroviral therapeutic regimens, such as 
single dose  nevirapine given to the infected mother at the onset of parturition 
and one dose to the new born infant within 72 hrs of birth, are of significant 
relevance to low- to mid-income countries because of low cost of above 
antiretroviral regime and the fact that in those nations perinatal care is often not 
properly utilised/ not available and pregnant women are seen by the health care 
workers for first time  near the time of delivery. These above factors increase 
the likelihood of HIV transmission. Apart from the above factors, others 
responsible for HIV transmission include detectable amount of HIV in breast 
milk, presence of mastitis, very low CD4+ T cell counts in mother and vitamin 
A deficiency in mother. The most important thing is that the risk of HIV 
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infection via breast milk feeding is much high during the initial months of 
breast-feeding.         
EPIDEMIOLOGY:- 
HIV Infection and AIDS Worldwide 
AIDS is an emerging global pandemic, with many cases reported from 
different country. By 2009, estimated 33.3 million patients were living with 
HIV infection/AIDS, based on the statistics released by the Joint United Nations 
Programme on HIV/AIDS (UNAIDS).
[47] 
More than 95% of patients living with HIV/AIDS dwell in low- and 
middle-income countries; 50% were female, and 2.5 million were children <15 
yrs. 
              
Populations in many Asian nations are very large (especially India and 
China) that even very low infection rate and sero-prevalence rate result in 
apparently large numbers of people living with HIV/AIDS. 
[48] 
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PATHOPHYSIOLOGY AND PATHOGENESIS:- 
The hallmark of AIDS/HIV disease is a massive lacunae in the defence 
system (immunodeficiency) resulting primarily from a progressive qualitative 
and quantitative deficiency of a subset of ‗T‘ lymphocytes termed to as ‗helper 
T cells‘ occurring in the setting of polyclonal immune cell activation. The 
helper T lymphocytes are phenotypically defined by the presence on their 
surface by the CD4 molecule, which functions as the cell‘s primary receptor for 
the Human Immunodeficiency Virus. A co-receptor must be present in the T 
lymphocytes together with CD4 molecule for an efficient binding, effective 
fusion, and proper entry of HIV-1 into its target cells (i.e., T Lymphocytes). 
HIV exploits these two major co-receptors, CCR5 and CXCR4, for their fusion 
and entry; these co-receptors function as the primary receptors for chemo 
attractive cytokines called chemokines and these belong to seven-
transmembrane-domain G protein coupled family of receptors. A number of 
other mechanisms are also responsible for depletion of immunological cells 
and/or immune dysfunction of CD4+ T lymphocytes have been shown in vitro. 
[49]
These include direct infection of these cells by HIV followed by their 
destruction, and the indirect effects such as immunological clearance of the 
infected cells and immune exhaustion/fatigue due to an aberrant cellular 
activation, and activation-induced apoptosis (cell death). Patients with CD4+ T 
lymphocytes levels beneath certain levels are at increased risk of 
communicating a wide variety of opportunistic disorders, particularly the 
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opportunistic infections and neoplasms that are AIDS-defining diseases. Some 
features/ disorders occurring in HIV/ AIDS, such as Kaposi's sarcoma and 
certain neurological abnormalities, cannot be completely explained  by the 
immune-compromise caused by HIV infection, since the above mentioned 
complications may occur well in advance to the development of severe 
immunologic disability. 
Virtually there exists, in all patients living with HIV/AIDS,  a pool of 
latently infected, dormant  CD4+ T lymphocytes that serve, at least, as one of 
the important component of the dormant  reservoir of virus. Such resting cells 
manifest post-integration latency (which means the HIV provirus integrates into 
the genome of the lymphocytes and can stay in this resting state until a 
provocative signal propels the expression/replication of HIV transcripts and 
ultimately replication-competent and infective virus). 
The picture below shows the viral invasion through the mucosal surface. 
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Immunological system activation and variable extend of the inflammation 
are crucial and essential components of any immune response to a foreign 
substance/ antigen. However, the activation of the immune system and variable 
inflammatory response can be considered significantly aberrant in a patient 
living with HIV/AIDS and they play crucial role in pathogenesis of the HIV 
disease and other important chronic inflammatory conditions associated with 
HIV/ AIDS.  Activation of the immune/ defence system and variable 
inflammatory response in the HIV-infected individual contribute substantially to  
(1)The replication of HIV virion,  
(2)Induction of the immune dysfunction, and  
(3)Increased incidence of chronic inflammatory/ non-inflammatory 
conditions associated with continuous/persistent immunological activation and 
inflammation 
 Bone fragility 
 Accelerated aging syndrome 
 Cardiovascular disease 
 Cancers 
 Kidney disease 
 Diabetes 
 Neurocognitive dysfunction 
 Liver disease 
20 
 
DIAGNOSIS OF HIV INFECTION IN SUSPECTED INDIVIDUAL/ AS A 
SCREENING PROCEDURE:- 
The Centre for Disease Control had recommended that the screening for 
HIV infection should be performed as a matter of routine health care. The 
diagnosis/ detection of HIV infection/ AIDS depend on direct detection of the 
HIV or one of the viral components/ antigen and/ or demonstration of the 
antibodies to Human Immunodeficiency Virus. As shown above, antibodies to 
the HIV generally appear in the systemic circulation 3–12 weeks following the 
inoculation of the infection. 
The standard serological screening test for detection of HIV infection is 
the Enzyme linked immunosorbant Assay (ELISA), which is also termed as an 
enzyme immunoassay (EIA). The above mentioned solid-phase assay is 
excellent and an extremely good screening measure with a sensitivity of about 
>99.5%. Most diagnostic laboratories utilise a commercial ELISA kit which 
contains antigens/components from both HIV-1 and HIV-2 and thus enable us 
to detect either infections. These kits utilise both recombinant and natural 
21 
 
antigens which are persistently updated to enhance their sensitivity to the newly 
discovered/ identified species, such as group O viruses. Fourth-generation 
ELISA test combines the detection of p24 antigen of Human Immunodeficiency 
Virus with the identification of the antibodies against HIV. ELISA tests are 
generally reported as positive (highly reactive), indeterminate (partially 
reactive) and negative (nonreactive). 
Only 10% of the ELISA-positive subjects are subsequently confirmed to 
have incurred HIV infection. There is humpty number of factors associated with 
the false negativity for ELISA test. Among those factors  
a) Antibodies to the class II antigens (may be seen after pregnancy, 
following blood transfusion, or transplantation), 
b) Hepatic disease,  
c) Autoantibodies, 
d) Acute viral infections and 
e) Recent influenza vaccination. 
The confirmatory test that is most commonly used - Western blot. This 
immunological assay encompasses the advantage of the fact that multiple HIV 
components/ antigens of well-characterized molecular weights invoke the 
production of specific antibodies. Those components/ antigens can be isolated 
on the basis of their molecular weight, and antibodies to each of those 
components can be identified as discrete/ separate bands on the Western blot 
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test. A negative Western blot is defined as one in which there is no bands 
present at molecular weights corresponding to the HIV gene products. In a 
patient identified with a positive or indeterminate ELISA and negative Western 
blot assay, one can conclude with the certainty that ELISA reactivity was false 
positive. On the other side, a Western blot assay demonstrating the antibodies to 
the products of all the three of the major genes of HIV (gag, pol, and env) one 
can conclude with certainty that the individual had definite evidence of HIV 
infection. Criteria published by the US FDA (Food and Drug Administration) in 
the year 1993 for a positive Western blot assay state that the result is termed 
positive/ reactive if antibodies to HIV gene products exist to two of the three 
HIV Antigens/ proteins:  p24, gp41, and gp120/160. Utilising these criteria, 
10% of all the blood donators deemed positive for HIV-1 infection didn‘t have 
an antibody band to the pol gene product p31. Some 50% of the above positive 
blood donators were subsequently found to be false positives. Thus, the lack of 
the p31 band should increase the doubt that one may be dealing a patient with a 
false-positive western blot test result. In this setting it is intelligent to obtain an 
additional confirmation with a RNA-based test for HIV-1 virion and/or a follow 
up Western blot assay. By the definition, patterns of reactivity in western blot 
assay that do not fall into either the positive or the negative categories are 
termed as "indeterminate‖ group. 
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Other diagnostic tests/modalities (such as RNA-PCR, DNA-PCR, the 
assay for bDNA, or p24 antigen capture) may be done to confirm that these 
bands do not indicate early HIV infection. 
FLOWCHART SHOWING THE STEPS INVOLVED IN THE 
DIAGNOSTIC PROTOCOL:- 
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ACUTE AIDS SYNDROME:- 
             
              
The Asymptomatic Stage—Clinical Latency 
Although length of the time from initial infection to the development of 
the clinical disease (i.e., incubation of infection) varies widely, the median time 
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for untreated patients is roughly about 10 years. As already emphasized above, 
the HIV/AIDS with an active viral replication/ multiplication is on-going and 
progressive during this asymptomatic stage/ period of clinical latency. The rate 
of the progression of the disease is correlated directly with the levels of HIV 
RNA. Patient with a very high plasma level of HIV RNA may progress to more 
symptomatic disease much faster than do patient with low plasma levels of 
HIV-RNA.  
Some patients are referred to as ‘long-term non-progressors’ may show 
little if there is any decline in T cell CD4+ counts over an extended period of 
time. These long term non-progressive patients generally have significantly very 
low levels of HIV-RNA;  
There is another subset of PLHA patients, termed as ‘elite non-
progressors’, who exhibits HIV-RNA levels <50 copies per millilitre.  
Certain patients remain entirely asymptomatic despite the fact that their T 
cell (CD4+) counts show a gradual/ steady progressive decline to significantly 
low levels. In this scenario, the appearance of an opportunistic disease 
(infection/ Malignancy) may be the primary manifestation of HIV infection/ 
AIDS.  
During this asymptomatic period/ clinical latency of HIV infection, the 
median rate of decline of the CD4+ T cell is roughly measures 50/µL per year. 
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When CD4+ T cell count falls to significantly low level i.e., <200/µL, the 
resulting immunodeficiency state is significantly severe enough to place the 
patient at a higher risk for both opportunistic infections and neoplasms and, 
thereby leading to a clinically apparent disease (symptomatic  disease). 
Symptomatic Disease:- 
Symptoms of the HIV disease (AIDS) can manifest at any point of time 
during the disease course of HIV infection. The spectrum of the illnesses may 
change widely as the CD4+ T cell count declines. The more severe and life-
threatening complications of HIV infection are encountered in PLHA patients 
with significantly very low CD4+ T cell counts i.e., <200/µL. A diagnosis of 
HIV/AIDS is done in any patient with HIV infection and a CD4+ T cell count 
<200/µL and in anyone with HIV infection who develops one of the HIV-
associated diseases considered to be indicative of a severe deficiency in cell-
mediated immunity. While the etiological agents of these secondary infections 
are typically opportunistic organisms such as atypical mycobacteria, P. jiroveci, 
CMV, and many other organisms that do not generally cause diseases in the 
absence of a defective immune system, they also encompasses common 
bacterial, viral and mycobacterial pathogens. After the widespread use of 
HAART and institution of the appropriate guidelines for the prevention and 
treatment of opportunistic infections and their control, the incidence of these 
secondary infections have dropped down dramatically. Overall, the clinical 
27 
 
spectrum of HIV disease/AIDS is constantly varying as these patients live 
longer and new and better methodologies to prophylaxis and treatment of HIV 
disease are significantly emerging day by day. In addition to the classical AIDS-
defining illnesses, patients living with HIV infection also have a dramatic raise 
in serious non-AIDS illnesses, including non-AIDS related carcinomas and, 
cardiovascular, metabolic, renal and liver disease. Non-AIDS incidences 
dominate the disease burden for these patients with HIV infection receiving 
HAART. Lesser than 50% of the deaths in AIDS patients are as a direct result 
of a classic AIDS-defining illness. The physician providing health care to the 
patient suffering from HIV infection must be well versed in general medicine as 
well as AIDS- related opportunistic diseases. In general, it should always be 
stressed that a key component of the treatment of symptomatic complications of 
the HIV/AIDS, whether they are primary or secondary, is achieving a good 
control of replication of HIV through the effective use of HAART and 
prescribing primary and secondary prophylaxis for opportunistic infections as 
and when indicated. 
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CD4 count and its relationship with the opportunistic infections: 
 
AIDS AND NON COMMUNICABLE DISEASES:- 
Heart disease is relatively common post-mortem finding in patient 
infected with HIV/AIDS (25–75% in the autopsy series). The most common 
form of heart disease is the coronary artery heart disease. In one large series, the 
overall incidence of myocardial infarction (MI) was about 3.5/1000 patient-
years, 28% of those events were fatal, and Myocardial infarction was 
responsible for about 7% of all deaths in the above cohort. In patients living 
with HIV infection, cardiovascular disease may be coupled with classical risk 
factors such as a direct consequence of HIV infection, smoking, or adverse 
reaction/ complication of HAART. Patients living with HIV infection have 
raised levels of triglycerides, reduced levels of high-density lipoprotein 
cholesterol, and a much raised prevalence of smoking than the cohorts of 
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individuals without HIV infection. The finding that the incidence of 
cardiovascular disease events was much lower in patients on antiretroviral 
therapy than in those randomized to undergo a treatment interruption recognised 
a clear correlation between HIV replication and cardiovascular disease risks. In 
one of the studies, a baseline CD4+ T cell count of <500/µL was detected to be 
an independent individual  risk factor for any cardiovascular disease events 
comparable in magnitude to that attributable to smoking. While the 
exact/precise pathogenesis of this correlation remains unclear, it is likely related 
to the inappropriate immune activation and an increased tendency for 
coagulation seen as a result of HIV multiplication. Exposure to certain reverse 
transcriptase inhibitors and HIV protease inhibitors has been correlated with the 
increase in total cholesterol and/or myocardial infarction risk. Any increase in 
the risk of death from Myocardial Infarction resulting from the utilisation of 
certain antiretroviral drugs must be balanced (benefit/ risk ratio) against the 
marked increase in overall survival rate brought about by these dreadful/darling 
drugs. 
Another form of the cardiovascular disease associated with HIV infection 
is dilated cardiomyopathy coupled with congestive heart failure (CHF) referred 
to as ‘HIV-associated cardiomyopathy’. This generally occurs as late 
complication of this viral (HIV) infection and, histologically, this depicts the 
elements of myocarditis. For this reason, some have advised treatment with IV 
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immunoglobulin (IVIg) which in-turn can subside/ allure the inflammation of 
myocardium. HIV can be demonstrated directly in the cardiac tissue in this 
setting, and there is a chronic debate over whether it plays a direct role in this 
condition. Patients present with typical findings of CHF including shortness of 
breath and edema. Patients with HIV infection may also develop 
cardiomyopathy as adverse effects of cytokines like IFN-α or drugs like 
nucleoside analogue therapy. Drug induced cardiomyopathy are reversible once 
therapy is put on red button.  
Kaposi Sarcoma, Chagas' disease, Cryptococcosis, and toxoplasmosis can 
affect significantly the myocardium, leading to opportunistic infection 
associated cardiomyopathy. In one series of studies, most patients living with 
HIV infection and treatable myocarditis were found to have toxoplasmosis 
associated myocarditis. Most of those patients also had an evidence of 
toxoplasmosis affecting their central nervous system. Thus, double-dose 
contrast CT scan or MRI of the brain should be inculcated in the workup of any 
of the patient with advanced HIV infection, significantly low CD4 count and 
cardiomyopathy. 
Lipid Profile 
A wide variety of endocrine and metabolic dysfunctions are seen in the 
context of patients living with HIV infection. These may be a direct 
consequence from infection due to HIV, or secondary to opportunistic 
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neoplasms or infections, or related to therapeutic (anti-retroviral therapy) side 
effects. Between 33 and 75% of these patients with HIV infection receiving 
HAART develop a syndrome often termed as ‗lipodystrophy‘, comprising of the 
elevations in plasma triglycerides, total serum cholesterol, and serum 
apolipoprotein B, as well as hyperglycaemia and hyperinsulinemia. Many of 
these patients have been noted to have characteristic set of body habitus changes 
associated with redistribution of fat, consisting of peripheral wasting coupled 
with truncal obesity. Truncal obesity is apparent as an increase in 
waist/abdominal girth related to increases in mesenteric fat, a dorso-cervical pad 
of fat ("buffalo hump") reminiscent of patients with Cushing's syndrome, and 
breast enlargement. The lipoatrophy, or peripheral wasting, is generally 
noticeable in the face and buttocks and by the venous prominence in the legs/ 
extremities. These changes may occur at any time ranging from 6 weeks to 
several years after the initiation of HAART. Approximately 20% of these 
patients living with HIV-associated lipodystrophy meet the criteria for the 
metabolic syndrome as defined by The U.S. National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) or The International 
Diabetes Federation (IDF). The lipodystrophy syndrome has been established in 
association with the regimens containing a variety of different anti-retro viral 
drugs, and while initially reported in setting of administration of protease 
inhibitor therapy, it also appears that similar changes can also be induced by 
potent and commonly used protease-sparing regimens. It has also been 
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suggested that these lipoatrophy changes are particularly much severe in 
patients receiving the thymidine analogues like stavudine and zidovudine. 
Guidelines established National Cholesterol Education Program (NCEP) should 
be followed in management of these lipid abnormalities. Due to these concerns 
regarding drug interactions, the most commonly utilized lipid-lowering agents 
in this setting are gemfibrozil and atorvastatin. 
 
Immune Reconstitution Inflammatory syndrome. 
[53, 05]
 
 
LIPID:- 
Screening: 
Guidelines for the management and screening of lipid related disorders 
have been provided by the expert Adult Treatment Panel (ATP) convened by 
the National Cholesterol Education Program (NCEP) of the National Heart, 
Lung, and Blood Institute. The NCEP ATPIII panel guidelines which were 
published in 2001 recommend that all adults older than 20 years of age should 
have plasma levels of the cholesterol, triglyceride, LDL-Cholesterol, and HDL-
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Cholesterol measured after a 12-hour overnight fasting. In most of the clinical 
laboratories, the total cholesterol and triglycerides in plasma are measured by 
enzymatic method, and then the cholesterol in the supernatant fluid is measured 
after the precipitation of apoB-containing lipoproteins to determine the HDL-
Cholesterol (which is an apoA containing substance). The LDL-Cholesterol is 
estimated using the following formula: 
 
 (The VLDL-Cholesterol is estimated simply by dividing the plasma 
triglyceride by 5, reflecting the proportion of cholesterol to triglyceride in 
VLDL particles.)  
This formula is reliable and accurate if the test results obtained are done 
in patients on fasting state and if the triglyceride level does not exceed more 
than 200 mg/dL; by convention the above formula cannot be used if plasma 
triglyceride level is >400 mg/dl; The accurate method for determination of 
LDL-Cholesterol levels in patients with triglyceride levels >200 mg/dL requires 
the application of ultracentrifugation techniques or any other direct assays for 
LDL-Cholesterol. If triglyceride level is more than 200 mg/dL, the guidelines 
recommend that the "non-HDL-C" be calculated by simple subtraction of HDL-
C from total cholesterol and that this should be considered as a secondary target 
of therapy. Further treatment and evaluation is primarily based on the plasma 
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LDL-Cholesterol and secondarily on non-HDL-Cholesterol levels as well as the 
assessment of overall cardiovascular risk factors. 
Diagnosis:- 
The crucial first step in management of lipid disorder is the determination 
of the class or classes of lipoproteins that are increased or reduced in the patient. 
The Fredrickson scheme of classification for hyperlipoproteinemias, although 
less commonly used now-a-days than in the past, can be helpful in this regard. 
Once the hyperlipidemia is accurately diagnosed/ classified, efforts should be 
targeted to rule out any possibilities of secondary causes of the hyperlipidemia. 
Although many of the patients with hyperlipidemia have a genetic cause of their 
lipid disorder (primary), secondary factors may frequently contribute to 
hyperlipidemia. Fasting plasma glucose should be obtained in preliminary 
workup of all the subjects with a raised plasma triglyceride level. Nephrotic 
syndrome and chronic renal failure should be excluded first by obtaining urine 
protein level and serum creatinine. Liver function tests should also be 
performed to rule out cholestasis and hepatitis. Hypothyroidism can be ruled out 
by measuring the serum level of TSH. Patients with hyperlipidemia, especially 
hypertriglyceridemia, who drink excessive alcohol, should be promoted to 
decrease their alcohol intake. Obesity, Sedentary lifestyle and smoking are 
important risk factors which were associated with low HDL-Cholesterol levels, 
and patients should also be counselled about these risk factor issues. 
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Once these secondary causes for the raised lipoprotein levels have been 
ruled out, every possible attempt should be made to diagnose the primary lipid 
disorder since the underlying causative agent has a significant effect on the risk 
of developing Coronary artery Heart Disease, on response to the drug therapy, 
and on management of other family members. Often, determining correct 
diagnosis requires a detailed history, family medical status and, in some cases, 
lipid analyses in rest of the family members. 
If fasting plasma triglyceride level is more than 1000 mg/dL, then the 
patient almost always has chylomicronemia and either has Type V or Type I 
hyperlipoproteinemia. The plasma triglyceride to total cholesterol ratio helps us 
to distinguish between the two possibilities and is much higher in Type I than 
Type V hyperlipoproteinemia. If the patient has Type I hyperlipoproteinemia, 
then post heparin lipolytic assay should be done to determine if the patient has 
Lipoprotein lipase or apoC-II deficiency. Type V is a much more common form 
of chylomicronemia in the adult patient than Type I. Often treatment of the 
secondary factors contributing to the hyperlipidemia (such as diet, glucose 
intolerance, obesity, alcohol consumption, estrogen therapy) will change a Type 
V into a Type IV pattern, reducing the significant risk of developing acute 
pancreatitis. 
If levels of LDL-Cholesterol are very high (i.e., greater than a ninety-fifth 
percentile), it is very likely that the patient has a genetic form of hyperlipidemia 
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(hypercholesterolemia). The presence of the severe hypercholesterolemia, 
tendon xanthomas, and autosomal dominant pattern of inheritance are consistent 
with the diagnosis of Familial Hypercholesterolemia, FDB, or ADH-PCSK9. At 
present time, there is no forcing reason to perform molecular level studies to 
further refine the molecular diagnosis, because the treatment of FH and FDB is 
same. Recessive forms of severe hypercholesterolemia are very rare and if 
patient with severe hypercholesterolemia has parents with normal cholesterol 
levels, sitosterolemia should be considered; a diagnostic clue for the identifying 
sitosterolemia is the greater than expected response of the hypercholesterolemia 
to reductions in dietary cholesterol content or to treatment with either a 
cholesterol absorption inhibitor (ezetimibe) or to bile acid resins. Patients with a 
moderate hypercholesterolemia, which does not clump in the families, are likely 
to have polygenic hypercholesterolemia. 
The most common error in the treatment and diagnosis of the lipid 
disorders occurs in patients with a mixed hyperlipidemia without any 
chylomicronemia. Elevation in the plasma levels of both cholesterol and 
triglycerides are seen in the patients with increased plasma levels of IDL (Type 
III) and of LDL and VLDL (i.e., Type IIB) and in patients with increased levels 
of VLDL (i.e., Type IV). The proportion of triglyceride to total cholesterol is 
higher in Type IV than the other two lipid disorders. The plasma levels of apoB 
containing lipids are highest in Type IIB. A beta quantification to determine the 
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VLDL-C/triglyceride ratio in plasma or a direct measurement of the plasma 
LDL-C should be performed at least once prior to initiation of lipid-lowering 
therapy to determine if the hyperlipidemia is due to the accumulation of 
remnants or to an increase in both LDL and VLDL. 
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ARTICLES SHOWING THE RELATIONSHIP BETWEEN THE CD4 
COUNT AND IMMUNODEFICIENCY:- 
The aim of the study conducted by Eric Walter Pefura Yone, Awa 
Foueudjeu Betyoumin, Andre Pascal Kengne, Francois Jerome Kaze Folefack 
and Jeanne Ngogang in Cameroon, was assessment of  prevalence, and the 
characteristics of  abnormalities of lipid profile in PLHA patient with or without 
ART that include nonnucleoside reverse transcriptase inhibitors (NNRTIs). 
They found that PLHA pts on first-line ART had high total cholesterol, LDL-c 
and TC/HDL-c ratio as compared with ART-naïve PLHA patients. Serum levels 
of HDL-c and triglycerides were not different between these two groups. The 
described derangements of lipid profile are potentially atherogenic. 
The conclusion of the above study was WHO first-line cART regimens 
containing NNRTIs are correlated with potentially atherogenic adverse lipid 
profile in HIV1/AIDS patients compared to untreated or treatment naïve PLHA 
patients. This indicates the need for updating the current recommendations of 
WHO concerning biological monitoring of PLHA on first-line cART to include 
lipid analysis. Lipid levels and any other cardiovascular risk factors should be 
closely monitored in these patients on such therapy so that any potentially life 
threatening effects of ART can be optimally managed 
[7]
.  
The conclusion of the study conducted by Dr. Christian Obirikorang, Dr. 
Francis Agyemang Yeboah, Lawrence Quaye et al., states that the lipid profile 
changes in PLHA can be correlated to the progression of the disease. Increase in 
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serum Triglycerides and the decrease in serum total Cholesterol, HDL 
cholesterol and LDL cholesterol could be helpful in the assessment of 
progression of disease, risk assessment for myocardial infarction and the 
clinical treatment of Ghanaian patients living with HIV/AIDS before 
introduction of HAART
 [8]
.  
 Previous studies conducted have shown that patients living with AIDS 
exhibit significantly abnormal complete lipid profile in plasma 
[9]
. Few authors 
[10, 11]
 who calculated/collected the concentration of plasma triglycerides, total 
cholesterol and HDL-c  in retrovirus infected individuals by the degree of 
immunological suppression according to the CD4 count, also came to a similar  
conclusion that, with an emergence or rise of immunological deficiency and 
clinical detoriation/ biochemical detoriation  in the form of  lipid profile 
derangement, indicated by an increase in triglyceride level and decreased 
concentrations of HDL cholesterol were intensified. The findings are also 
consistent with reports from Ducobu and Payen, 2000 
[10]
 who declared that 
HIV infection induced an early lowering of cholesterol and a late rise of 
triglyceride with a lowering of HDL. The lipid profile changes are proportional 
to the decrease of CD4 count, which reflected the infection i.e., HIV infection 
severity, as was the case in this study. Shor-Posner et al., (1993) 
[12]
 reported 
same findings in which they demonstrated significantly decreased levels of total 
cholesterol, HDL, LDL cholesterol in HIV/AIDS patients when compared with 
that of seronegative controls (P < 0.05). This decreased level of total, LDL, 
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HDL cholesterol was reported to be due to elevated levels of beta-2 
microglobulin 
[4].
  
The reduced cholesterol levels are prevalent even during early stages of 
HIV infection and were correlated with a specific change in immune function 
[12].
 The results of the study showed that increase of triglycerides in HIV 
positive patients occurs at a later stage of disease. This hypertriglyceridemia, 
demonstrated by other authors 
[13, 14]
 was correlated with opportunistic infections 
and interferon-α. The association between interferon-alpha (IFN-α) and 
triglycerides (TG) patients living with HIV/AIDS has been previously 
established by Grunfeld et al (1991) 
[8].
 IFN-α may raise TG by two important 
mechanisms:  
1) A reduction in TG clearance; and  
2) A raise of de novo hepatic lipogenesis (lipid production) and increased 
VLDL production.  
The hepatic lipogenesis may be enhanced by three cytokines as follows: 
Interleukin 1 and 6 (IL-1 and IL-6) tissue necrotic factor- alpha (TNF-α). IL1 
and 6 increase hepatic levels of citrate; and IFN-α that does not increase hepatic 
citrate. Both depressed TG clearance and increased hepatic VLDL 
overproduction were found in patients living with HIV/AIDS, and the increased 
hepatic lipogenesis correlates to IFN-α [15]. 
 Acute opportunistic/ any other infections might increase TG level by the 
increasing the level of hormones (steroids) or cytokines other than TNF-α or 
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IFN-α. Decrease in cholesterol, especially HDL-C occurs in HIV-seropositive 
patients at an earlier stage much more before the development of 
hypertriglyceridemia. These abnormalities of cholesterol metabolism have been 
suggested by others 
[12, 16].
 TNF-α has been hypothesised/found to play a crucial 
role in the peroxidation of plasma lipoproteins and lipids in animals and in 
patients through stimulation of the production of oxygen reacting species
 [17].
 
Lipid peroxidation, in part, may explain the abnormalities of cholesterol 
metabolism in patient living with HIV/AIDS and these modifications would 
have important impact on the immune dysfunction. Studies show that 
dyslipidaemia in patients living with HIV/AIDS carries the very same degree of 
cardiovascular risk as in HIV-negative population 
[18]
. 
The serum concentrations of TGL 
[19] 
and HDL-cholesterol are considered 
independent risk factors for coronary artery disease 
[20, 21]
.  Stampfer et al., 
(1996) 
[22] 
in his study of TGL level and its association with risk of myocardial 
infarction concluded that raised triglyceride level, smaller LDL particle 
diameter and reduced HDL-cholesterol levels appear to indicate underlying 
metabolic perturbations with negative consequences for risk of myocardial 
infarction (MI); raised triglyceride levels may help us identifying high-risk 
individuals who are likely to develop Myocardial infarction. 
With the introduction of HAART in late 1990s, HIV associated morbidity 
and mortality in patients receiving HAART, have significantly decreased so that 
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they no longer die due to opportunistic infections.
[23]
 This is true, especially in 
developed countries which have significant health advances. The international 
donors and organizations have put a huge effort, which in turn have assisted in 
providing easy access to Highly Active Anti-Retroviral Therapy in most of the 
developing countries like Nigeria. However, patients living with HIV/AIDS are 
subjected to dyslipidaemia and other complications secondary to HAART 
which are often termed as HIV metabolic syndrome
 [24]
.  
Even before the use/availability of HAART, studies in HIV infected 
individuals have demonstrated a variety of lipid abnormalities.
 [25, 2 6]
 Low levels 
of total cholesterol (TC), HDL - cholesterol and Low density Lipoprotein 
cholesterol (LDL) have been shown in HIV infection 
[25]
. Mondy K et al 
reported low HDL and high TG in their study group in the US
 [27]
. In Uganda, 
recent studies showed that HIV infected patients have infrequent rise in serum 
TC, LDL and TGL.
 [28]
 
The correlation between HAART especially Protease Inhibitor (PI) based 
regimen and the incidence of abnormal lipid and lipoprotein profiles is well 
known.
 [29]
 In another study, HIV-infected ART-naïve subjects had decreased 
concentrations of LDL and HDL and a higher concentration of TG than healthy 
controls. After receiving Protease Inhibitor based Anti-Retroviral Therapy, 
LDL-Cholesterol and TGL concentrations increased, while HDL-C 
concentrations remained unchanged 
[30]
. However, Nevirapine based regimen 
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has shown to increase TC, HDL and these changes start even at 24 weeks of 
treatment. 
[31]
 
In Nigeria, Akpa MR et al, has studied the serum lipid profile levels in 
healthy Nigerians 
[32]
. They found that mean TC and LDL concentrations were 
elevated but Triglyceride (TGL) and HDL were reduced. In a similar work i.e., 
lipid profile among patients with type 2 diabetes, several permutation and 
combinations of abnormal lipid concentration including reduced HDL and 
raised TG were noted. 
[33]
 
However, data about various patterns of lipid profile in treatment naïve 
HIV positive patients is very minimal. We hypothesized that treatment naïve 
patients living with HIV/AIDS in our environment, have various abnormal lipid 
profiles which were quite different from HIV negative persons. Secondly, even 
the short term treatment with HAART like post exposure prophylaxis has an 
impact on lipid level 
  Increased level of serum TG was recorded among patients living with 
HIV/AIDS, though this may not be significant. The levels of TG and HDL fit 
the criteria for dyslipidaemia as defined by the National Cholesterol Education 
Program (NCEP-ATP III), with serum level of less than 1.03mmol/l and greater 
than 2.3mmol/l respectively
 [35]
. Although the mean LDL was significantly 
greater than the control, this did not reach dyslipidemic level. The finding of 
reduced HDL in treatment naïve patients living with HIV/AIDS was similar to 
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the Nutrition for Healthy Living (NFHL) cohort in the United States 
[36]
. In that 
study, HIV patients who are not yet started on HAART have an adjusted OR of 
2.7 for low HDL compared with that general population. This is strongly 
supported by recent studies in Spain 
[37]
. This finding of decreased HDL is also 
similar to conclusion obtained among diabetics, diabetics and hypertensive in 
Nigeria
 [38]
. 
Reduced HDL is a well-recognized important and independent risk factor 
for adverse cardiovascular disease events and this has been shown to be true in 
HIV infected patients, irrespective of any other associated risk factors
 [39]
. 
An important finding is corroborated by the findings of Shor-Posner et al, 
where reduced cholesterol without or with raised triglyceride was seen in male 
patients with an early HIV -1 infection
 [39]
. Decreased level of cholesterol has 
been shown in AIDS, early HIV infection and some other infections
 [40, 41]. 
This 
has been found to be inversely related to Tumor Necrosis Factor-alpha (TNF-
alpha)
 [39]
, but the pathophysiological mechanisms are not yet clear 
[39]
. 
The lack of correlation between any of the lipid parameters and 
hypertension may be associated to the duration of hypertension, the degree of 
the blood pressure control or extend of immune suppression. Even in previously 
diagnosed hypertensive patients, who have been on medications or those with a 
strong positive family history of adverse cardiovascular events in their first 
degree relative, there were no significant association between hypertension and 
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abnormal lipid profile, especially reduced HDL 
[38]
. This may signify that HIV 
infection may contribute to an additional and independent cardiovascular risk 
factor in hypertensive patients. 
The reason for lack of relationship between lipid parameters in the study 
group of patients living with HIV/AIDS and the immune status may be due to 
the close resemblance in the CD4 count as most these patients are in the CD4 
count ranging from 50 to 220cell/mm3. Despite this, it has been shown that the 
decrease in HDL in HIV infection persists all along different CD4 levels from 
the beginning of infection 
[39]
. Raised TGL was shown to directly correlate with 
interferon alpha levels, advanced / opportunistic infection when immunity is 
markedly compromised and delayed/slow clearance due to compromised 
lipoprotein lipase activity. 
[42, 43]
  
Case reports have described that the HIV-infected patients who were 
ApoE ε2 or ε4 carriers in whom severe hyperlipidaemia was triggered by the 
initiation of HAART 
[54]. ApoE ε4 carriage was already been linked to 
hypertriglyceridemia in advanced HIV infection in the pre-HAART era 
[54]
 
A more recent report showed an association of hypertriglyceridemia with 
variant alleles of ApoC3 in 60 men who all were treated with PI based HAART 
[51]
. TG levels were higher in carriers of three variant ApoC3 alleles than in 
carriers of one or two variant alleles. An association of these ApoE and ApoC3 
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variants with hyperlipidaemia was recently reported in a longitudinal study of 
329 HIV infected patients in the Swiss HIV cohort study 
[14]
.  
The genetic variants were relatively common: 27.7% of patients were 
carriers of variant alleles of ApoE (i.e., ε2 or ε4 alleles), 17.9% were carriers of 
all three variants of ApoE, 5.8% were carriers of variants of both ApoC3 and 
ApoE; and these patients were at risk for extreme and sustained 
hypertriglyceridemia when exposed to RTI. The relative contribution of 
genotype and HAART to lipid levels was also evaluated. HAART containing a 
PI but no RTI, and RTI containing HAART were associated with increases in 
non –HDL-C of 0.29mmol/l (11mg/dl) and 0.65mmol/l (25mg/dl), respectively. 
The contribution of the ApoE ε4 allele was a non – HDL-C increase of 0.27 
mmol/l (10.4mg/dl) i.e., quantitatively similar to the non-HDL-C increasing 
effect of PI treatment 
[14]
. This study highlighted the issues of appropriate 
methodology and statistical power in genetic association studies. Longitudinal 
modelling of lipid levels in large numbers of patients may represent the most 
important and the powerful approach to quantitating the contributions of 
genotype and HAART to dyslipidaemia. Cross-sectional analyses of lipid levels 
at a single time point during HAART exposure may be underpowered to detect 
the genetic effects. 
[54]
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CARDIOVASCULAR RISKS IN HIV-INFECTED PERSONS 
Several cases of premature coronary Heart Disease (CHD) have been 
reported in HIV patients with dyslipidaemia associated with HAART 
[56-61]
. 
In a cross sectional study, HIV infected individuals had more femoral or carotid 
artery atherogenic plaques than controls. However most of these patients had 1 
or more established CHD risk factors like Diabetes mellitus, Smoking, 
Hypertension etc. A recent large cohort study showed higher age-adjusted rates 
of coronary Artery Heart Disease in the HIV infected individuals compared 
with HIV negative individuals (6-3 versus 2.9/1000 person years, 
respectively)
[62]
. The most solid data linking HAART exposure to an increased 
cardiovascular risk to date was provided by the DAD study. In the most recent 
analysis of DAD data, the adjusted risk of myocardial infarction (MI) was 
increased by 17% for each year of HAART exposure, 16-18% for each mmol/l 
increase in T-Cholesterol, and 39-48% for each doubling of the TG 
concentration 
[63]
. It is clear that the benefits of HAART outweigh the small, 
absolute increase in cardiovascular risk that is presumably attributable to the 
HAART 
[64]
. In the DAD study, the risk of MI was 1.39/1000 patient years in 
those not exposed to HAART. The risk increased 2.53/1000 in those <1year of 
exposure, and 6.07/1000 in those exposed to >6 years of HAART. The exact 
mechanisms by which premature atherosclerosis is mediated in HIV infected 
person is unclear. Support for direct pro-atherogenic effects is provided by 
studies showing that HAART and HIV infection itself may induce endothelial 
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dysfunction 
[65-67]
, an early indicator of atherosclerosis associated with 
diminished vasodilatory properties of the endothelium. A high proportion of 
HIV infected individuals can be classified as being at high 10-year 
cardiovascular risk. Among 3199 HIV-infected patients evaluated in Spain in 
2004, 10% of women and 29% of men were considered to be at either 
moderately high or high 10 year CAD risk 
[68]
. 
With the improved life expectancy since the introduction of HAART and 
the consequent ageing of the HIV-infected population, the number of patients at 
high cardiovascular risk is likely to increase. This has already been shown in the 
DAD cohort, in which the proportion of patients at high risk increased from 
36.2% in 2000 to 44.7% in 2003 
[69]
. After adjusting for changes in cardiac risk 
factors, however, the MI risk was lower in 2003-2004 compared with 1999- 
2000. The exact reasons for this decrease in MI risk are not yet clear. Several 
changes over time have been noted in the DAD cohort, including a decrease in 
PI use (2000:47.4%, 2003: 40.1%), an increase in NNRTI use (2000:32.6%, 
2003: 38.5%), an increase in patient receiving lipid-lowering therapy (2000: 
4.0%, 2003: 8.1%), and an increasing proportion of ex-smokers (2000: 15.7%, 
2003: 24.9%). Such trends have also been recorded in other studies, and suggest 
that physician awareness of cardiovascular risk is increasing 
[62, 70 and 71]
.  
In a large cohort study from California, the use of d4T decreased, and the 
use of ATV and lipid-lowering therapy increased during the study period (1996-
2004) 
[62]
. More widespread use of lipid-lowering therapy in the most recent 
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years and a tendency to usage PIs more sparingly has also been noted in a study 
from Tennesse 
[72]
. In the French Aquitaine Cohort of HAART-treated patients, 
a decrease in the prevalence of smoking, decreased PI use and an increase in the 
use of lipid lowering medication were noted between year 2000 and year 2004, 
along with significant decrease in the intimal media thickness 
[71]
. Although the 
effect on cardiac outcomes remains to be confirmed, each of these studies 
suggests the feasibility and potential efficacy of interventions aimed at 
cardiovascular prevention in HIV-infected patients. 
 
EFFECTS OF SWITCHING THE ANTIRETROVIRAL THERAPIES 
The association between increased serum lipid levels and certain 
antiretroviral therapies had led to exchanging the potentially offending 
component for another drug. This switching strategy has the potential advantage 
of avoiding the pharmacologic intervention for elevations in lipid levels. 
However, because of the multifactorial nature of dyslipidemia in HIV infection, 
abnormalities may not resolve simply by switching drugs. Switching from a PI 
to nevirapine or abacavir has generally resulted in an improvement in total 
cholesterol and triglyceride levels 
[73-81]
, whereas switching to efavirenz has 
produced less consistent results 
[82]
. These trials have generally depicted the 
persistent viral growth suppression for 6-12 months after switching regimens. In 
patients with a favourable treatment history (i.e., no previous intake of an RTI-
based antiretroviral regimen that was less than fully suppressive and also it have 
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been shown that there was no virological rebound for patient receiving NRTI 
based ART regimen), switching from lipid raising Protease Inhibitor to abacavir 
or nevirapine may be more preferred than the pharmacologic intervention with a 
lipid lowering drug. In practice, however, many of the patients will have already 
received NNRTI therapy. Various studies comparing the different effects of 
therapies like switching of ART drugs to those of adding lipid lowering 
medications to on-going newer research level therapy have not yet been 
properly reported. Physicians should have to weigh the risks of newer 
treatment-related toxicities/ adverse effect and the possibility of viral relapse 
when switching between various antiretroviral drugs regimens. Clinician should 
also consider the risks of potential drug interactions and new treatment-related 
toxicities due to lipid-lowering agents when added to existing antiretroviral 
regimens. 
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MATERIALS AND METHODS 
This is a cross sectional study conducted in Government Kilpauk Medical 
College Hospital, Department of medicine in collaboration with ART centre, for 
a period of 7 months. A total of 100 cases attended the out-patient department/ 
admitted in medical ward with HIV/AIDS and who were not on HAART were 
selected for the present study from May 2013 to November 2013. 
   Among 100 patients studied 50 cases are Patients living with HIV/AIDS 
who were not on HAART (as case) and rest 50 are those who attended 
outpatient department (as control) 
Patients who fulfil inclusion and exclusion criteria were enrolled for the 
study after obtaining written informed consent. The study protocol was 
approved by the ethical committee of Govt. Kilpauk medical college hospital, 
Chennai-10 for research studies conducted on April, 2013. 
 
Inclusion criteria 
Patients admitted in medical wards/ attended outpatient department/ ART 
centre of Govt. Kilpauk medical college hospital, 
 Patients in the age group of above 18 years 
 Patients proven to have HIV/AIDS by ELISA/& western blot techniques 
(in cases only) 
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Exclusion criteria 
Medical conditions and patients who were on drugs which alters the lipid 
profile are excluded from study like 
1. Patient who don‘t have family history of dyslipidemia 
2. Not a diabetic, hypertensive/ CAD/ CKD patient 
3. Not on drugs causing dyslipidemia 
4. Not started on Highly active antiretroviral therapy(in case only) 
5. No history of any opportunity infection 
Data collection 
Detailed history was taken from the patients that includes onset of 
symptoms, past medical history and thorough physical examination and 
systemic examination was done and entered in proforma specially designed for 
this study. 
Blood investigations 
In all patients who are selected for the study, routine investigations like 
complete blood count and urine examination were done. Biochemical 
parameters like random blood sugar, fasting lipid profile and CD4 count for 
PLHA case were done. Body Mass Index was calculated for all the patients 
selected for the study 
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METHODOLOGY OF INVESTIGATIONS 
 
HIV serology was done using micro ELISA kit.  
 
CD4 count was done with FACS count (Automated Counter) manufactured 
by Becton and Dickinson.  
Lipid profile analysis was done on serum obtained after 12 hours of fasting. 
Total cholesterol, triglycerides and HDL-C are measured  
Tests were done in a single laboratory by the same person. Therefore no 
interpersonal error was possible. 
The normal values of the parameters taken for the study were assessed and 
listed below. 
 
Total Cholesterol (TC) 
 
Desirable TC is less than 200mg/dl 
 
Borderline high TC is from 200-239mg/dl 
 
High TC is greater than or equal to 240mg/dl 
 
 
HDL Cholesterol (HDL-C) 
Desirable HDL-C is greater than or equal to 40mg/dl (50mg/dl in female) 
 
Low HDL-C is less than 40mg /dl (50mg/dl in female) 
 
 
Triglycerides (TG) 
Desirable Triglycerides is less than 150mg/dl 
 
Borderline high TG is from 150 to 199mg/dl 
 
High TG is from 200 to 499 mg/dl 
 
Very-high TG is greater than 500mg/dl 
 
54 
 
Patient living with HIV/AIDS were grouped based on WHO Clinical 
Staging (National Aids Control Organisation) 
 
Statistical Tools 
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using statistics 
software (SPSS). 
Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chi-square 
test was used to test the significance of difference between quantitative 
variables and Yate‘s test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
Sensitivity, specificity, accuracy, positive predictive value and negative 
predictive values were calculated using the following formulae 
Sensitivity =                      True positive                             x 100 
                        True positive + False negative 
 
Specificity =      True negative                            x 100 
      False positive + True negative 
 
Accuracy =        True Positive + True Negative          x 100 
Total cases 
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Positive predictive value =         True positive               x 100 
    True positive + False positive 
 
Negative predictive value =          True negative               x100 
    True negative + False negative 
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OBSERVATIONS AND ANALYSIS 
Table 1 
Age distribution among Cases and Controls 
Age group Cases Controls 
<30 yrs 0 3 
30 - 39 yrs 6 9 
40 - 49 yrs 18 14 
50 - 59 yrs 18 15 
>60 yrs 8 9 
  
Out of 50 cases of Patient Living with HIV/ AIDS (PLHA) studied 
majority of patients belong to the 
a) Age group of 40 to 49 (36%) and  
b) Age group of 50 to 59 (36%). 
 
Chart 1a 
 
<30 yrs 
0% 
30 - 39 yrs 
12% 
40 - 49 yrs 
36% 50 - 59 yrs 
36% 
>60 yrs 
16% 
Age distribution among Cases 
57 
 
 
Chart 1b 
 
 
Out of 50 normal persons (controls) studied majority of patients belong to the 
a) Age group of 50 to 59 (30%) and  
b) Age group of 40 to 49 (28%) 
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Table 2 
Gender distribution among Cases and Controls:-   
Gender Cases Controls 
Male 21 19 
Female 29 31 
 
The gender distribution among the PLHA patients and normal persons 
compared in our study are matched appropriately as shown in the table above 
and the chart depicted below. 
 In our study the prevalence of disease appears to be more common in 
female 
 
Chart 2 
Gender distribution among Cases and controls 
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Table 3 
Number of Cases based on WHO categories:-  
WHO categories No. of persons 
I 14 
II 14 
III 12 
IV 10 
  
 In our study, there was significantly higher number of Patients Living 
with HIV/AIDS in category I/II when compared with that of patient living in 
category III/IV 
Chart 3 
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Table 4 
Distribution of BMI among Cases and Controls:-  
BMI Cases Controls 
<18.5 1 0 
18.5 to 24.9 31 26 
25 to 29.9 18 23 
>30 0 1 
 
 In our study, about 62% of the patients living with HIV AIDS were in the 
normal range of body mass index and 36% of cases were in pre-obesity range. 
 Among the control population, 52% of the persons were in normal range 
and 46% of persons were in pre-obesity range 
 
Chart 4 
 
0
5
10
15
20
25
30
35
<18.5 18.5 to 24.9 25 to 29.9 >30
Distribution of BMI among Cases and Controls 
Case
Control
61 
 
 
Table 5 
CD4 count among the Cases:- 
CD4 count Case 
>500 12 
200 to 499 27 
<200 11 
 
 In our study group, majority of the HIV infected population had a CD4 
count in the range of 200- 499 (54%), where as 24% had CD4 count more than 
500 and 22% had CD4 count less than 200 
 
 
 
Chart 5 
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Table 6 
Triglyceride distribution among Cases and Controls:-  
TGL Case Control 
<150(desirable) 9 19 
150-199(borderline 
high risk) 
11 21 
200-499 (high risk) 27 10 
≥500 (very high risk) 3 0 
 
 In our study group, among cases there is a very good number of cases 
(PLHA) had a high risk triglyceride range where as in control population, 
majority of population had a borderline high risk (42%) and desirable 
triglyceride range (38%) 
Chart 6 
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Table 7 
Cholesterol distribution among Cases and Controls:-  
CHO Cases Controls 
<200 36 40 
200-239 8 9 
≥240 6 1 
  
 From the above chart, it is very clear that the percentage of population 
having desirable cholesterol level is higher among the controls (80%) when 
compared with that of the cases (72%). It is also shown that the patient having 
‗very high risk‘ cholesterol level is significantly higher among the cases (12%) 
when set side by side with that of controls.   
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Table 8 
LDL distribution among Cases and Controls:-  
LDL Cases Controls 
<100 32 21 
100-129 11 21 
130-159 4 8 
160-189 2 0 
≥190 1 0 
 
 The percentage of population having ‗desirable‘ cholesterol is high in 
cases (62%) than controls (42%). It appears that HIV infected population had a 
significantly lower level of LDL when compared with that of normal 
population. 
Chart 8 
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Table 9 
HDL distribution among Cases and Controls:-   
HDL Case Control 
 Male Female Male Female 
<40 7  6  
≥40 14  13  
<50  24  27 
≥50  5  4 
   
 Among male cases 33% had riskier level of HDL level and the rest (66%) 
had protective level of HDL. This was comparable to that of control male 
population. 
 Among Female cases 82% had riskier level of HDL level while the rest 
(18%) had protective level. In control population (female) 87% of female are in 
the riskier range of HDL cholesterol. 
Chart 9
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Table 10 
Age VS Dyslipidemia in Cases and Controls:- 
 
Age TGL Cholesterol HDL LDL 
  
<
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C
as
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<30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
30 – 39 0 1 5 0 5 1 0 1 3 2 0 4 1 1 0 0 
40 – 49 5 5 7 1 13 2 3 2 6 8 2 8 4 2 3 1 
50 - 59 3 3 11 1 12 6 0 2 11 2 3 11 6 0 1 0 
>60 1 2 5 0 6 2 0 2 3 3 0 6 0 2 0 0 
C
o
n
tr
o
ls
 <30 1 1 1 0 3 0 0 1 1 1 0 1 1 1 0 0 
30 - 39 2 7 0 0 6 3 0 2 1 6 0 1 3 2 2 1 
40 - 49 7 3 4 0 13 1 0 1 5 6 2 1 6 6 1 0 
50 - 59 8 5 2 0 10 5 0 1 12 0 2 2 2 6 5 0 
>60 1 5 3 0 8 1 0 1 7 0 1 0 4 4 1 0 
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Table 11 
Gender vs Dyslipidemia in Cases and Controls:-   
 Gender TGL Cholesterol HDL LDL 
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Cases Male 5 4 12 0 14 4 3 7  14  11 5 4 1 0 
Female 5 8 14 2 22 4 3  23  6 20 6 1 1 1 
                  
Controls Male 5 9 5 0 15 3 1 6  13  2 5 8 3 1 
Female 14 12 5 0 25 6 0  27  4 3 11 11 6 0 
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Chart 11b 
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Table 12 
Dyslipidemia distribution among various categories of HIV:- 
Staging TGL Cholesterol HDL LDL 
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Table 13 
BMI vs. Dyslipidemia in Cases and Controls:- 
 BMI TGL Cholesterol HDL LDL 
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Chart 13b 
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Table 14 
Dyslipidemia distribution in HIV patients categorised based on CD4 
count:-  
CD4 
count 
TGL Cholesterol HDL LDL 
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Chart 14b  
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Chart 14d 
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Table 15 
Correlation of CD4 count with BMI:- 
CD4 count BMI 
 <18.5 18.5 - 24.9 25 -29.9 >30 
<200 0 9 3 0 
200 - 499 1 17 9 0 
≥ 500 0 5 6 0 
 
 Among the cases in our study, it is very clear from the above tabular 
column that irrespective of CD4 categorisation, majority of case population 
have normal body mass index. 
And also we could appreciate in our study that the distribution of HIV 
infected person was found to reside significantly in 200 to 499 range of CD4 
count category. 
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Table 16 
Correlation of CD4 count with HIV categories:-  
CD4 count Category 
 I II III IV 
<200 1 2 4 5 
200 - 499 7 11 5 4 
≥ 500 6 5 0 0 
Among cases, 
Majority of patients in category III and IV have CD4 count < 500 while 
majority of patient in Category I and II have CD4 count more than 200 
 Similarly, majority of population with CD4 count <200 are in category III 
and IV whereas majority of population with CD4 count > 200 are in category I 
and II 
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STATISTICS AND ANALYSIS:- 
Age distribution among cases and controls 
 Group N Mean Std. Deviation P value 
Age in 
years 
Controls 50 47.94 11.304 
0.271    
Cases 50 50.20 8.985 
 
 There is no significant difference in the age distribution among cases and 
controls. That is, in my study, age distribution was matched between cases and 
controls. 
CD4 count Vs. Lipid profile 
   N Mean Std. Deviation Range 
P- value 
          Minimum Maximum 
TGL 
  
  
  
Up to 199 12 272.67 146.052 76 492 
  
  
 
0.807 
200-499 27 245.56 121.378 94 553 
500 and 
above 
11 246.73 97.683 162 456 
Total 50 252.32 121.190 76 553 
TC 
  
  
  
Up to 199 12 191.08 44.874 115 254   
 
 
 
 
0.129  
200-499 27 166.22 32.032 110 226 
500 and 
above 
11 203.18 93.971 126 439 
Total 50 180.32 55.262 110 439 
HDL 
  
  
  
Up to 199 12 42.08 6.921 33 58  
  
 
 
0.848 
200-499 27 43.19 5.609 24 51 
500 and 
above 
11 43.09 3.986 39 50 
Total 50 42.90 5.560 24 58 
LDL 
  
  
  
Up to 199 12 94.467 44.8088 41.8 178.2  
  
 
 
0.148 
200-499 27 73.926 40.0038 15.4 145.0 
500 and 
above 
11 110.745 84.8076 44.6 328.0 
Total 50 86.956 54.7916 15.4 328.0 
VLDL 
  
  
  
Up to 199 12 54.533 29.2104 15.2 98.4  
 
 
 
 
0.807 
200-499 27 49.111 24.2756 18.8 110.6 
500 and 
above 
11 49.345 19.5367 32.4 91.2 
Total 50 50.464 24.2379 15.2 110.6 
 There is no significant correlation between the CD4 count and the Levels 
of various parameters of lipid profiles 
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Gender vs. BMI distribution:- 
 
  
Group Total 
P- value 
   Control Cases   
 
 
 
 
 
 
 
0.683 
Male Count 19 21 40 
  % within 
Sex 
47.5% 52.5% 100.0% 
Female Count 31 29 60 
  % within 
Sex 
51.7% 48.3% 100.0% 
Total 50 50 100 
 
 The distribution of BMI among different sex groups in cases and controls 
are not statistically significant. 
 This implies that the sex has effect on Body Mass Index in neither cases 
nor control. 
WHO categories Vs. CD4 count 
 N Mean Std. Deviation Range 
P value 
        Minimum Maximum 
 
 
 
 
 
 
<0.001** 
I 13 499.23 206.306 209 882 
II 18 419.61 192.319 17 837 
III 10 205.80 114.858 42 398 
IV 9 197.89 92.826 76 318 
Total 50 357.64 207.865 17 882 
 
 There was a very significant correlation between CD4 count and WHO 
categories for HIV infection 
Post Hoc test (Tukey HSD test) 
WHO Categories N 
Subset for alpha = .05 
    
1 
2 
IV 9 197.89   
III 10 205.80   
II 18   419.61 
I 13   499.23 
Sig.   .999 .673 
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 This above post hoc test demonstrates that there is a significant difference 
between the distributions of CD4 count among WHO categories I, II and III, IV. 
This also shows that as the patient deteriorates down the WHO categories, the 
CD4 count significantly comes down 
WHO categories Vs. Dyslipidemia 
Dyslipi
demia 
 WHO 
catego
ries 
  
No. of 
cases Mean Std. Deviation Range 
P- value 
      Minimum Maximum 
TGL 
  
  
  
  
I 13 264.15 156.019 120 553 
 
 
 
 
0.978 
II 18 251.72 96.328 94 412 
III 10 242.30 102.913 76 441 
IV 9 247.56 146.397 110 492 
Total 50 252.32 121.190 76 553 
TC 
  
  
  
  
I 13 169.08 43.786 131 279 
  
 
 
 
0.847 
II 18 187.50 74.136 110 439 
III 10 181.40 47.596 115 254 
IV 9 181.00 35.746 136 246 
Total 50 180.32 55.262 110 439 
HDL 
  
  
  
  
I 13 44.85 4.059 40 50 
  
  
 
 
0.438 
II 18 42.83 4.706 35 51 
III 10 41.10 9.012 24 58 
IV 9 42.22 3.930 38 50 
Total 50 42.90 5.560 24 58 
LDL 
  
  
  
  
I 13 71.400 41.7051 24.4 147.8 
0.702 
II 18 94.322 74.2478 15.4 328.0 
III 10 91.840 40.2504 41.8 157.8 
IV 9 89.267 41.1178 43.4 178.2 
Total 50 86.956 54.7916 15.4 328.0 
VLDL 
  
  
  
  
I 13 52.831 31.2037 24.0 110.6 
 
 
 
 
 
0.978 
II 18 50.344 19.2657 18.8 82.4 
III 10 48.460 20.5826 15.2 88.2 
IV 9 49.511 29.2794 22.0 98.4 
Total 50 50.464 24.2379 15.2 110.6 
 
 In our study, from the above table, it is very clear that the distribution of 
various parameters in lipid profile has no pattern/ statistical correlation among 
the various WHO categories of the HIV infected person. (P values correlating 
various parameters and WHO categories are very much higher than 0.05) 
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BMI Vs. Dyslipidemia in cases and controls 
   N Mean Std. Deviation Range 
 
          Minimum Maximum 
 
TGL 
  
  
  
Normal 26 188.38 77.964 126 412 
 
0.66 
Overweight 23 172.13 60.474 122 420 
Obese 1 152.00 . 152 152 
Total 50 180.18 69.466 122 420 
TC 
  
  
  
Normal 26 170.58 26.297 126 210  
 
 
 
0.32 
Overweight 23 182.22 27.709 120 240 
Obese 1 178.00 . 178 178 
Total 50 176.08 27.044 120 240 
HDL 
  
  
  
Normal 26 40.42 2.436 34 46   
  
 
 
0.68 
Overweight 23 41.13 3.494 34 54 
Obese 1 40.00 . 40 40 
Total 50 40.74 2.940 34 54 
LDL 
  
  
  
Normal 26 92.477 34.7206 17.6 144.0 
 
 
 
0.32 
Overweight 23 106.661 30.8317 27.0 158.4 
Obese 1 107.600 . 107.6 107.6 
Total 50 99.304 33.0666 17.6 158.4 
VLDL 
  
  
  
Normal 26 37.677 15.5928 25.2 82.4  
 
 
 
0.66 
Overweight 23 34.426 12.0948 24.4 84.0 
Obese 1 30.400 . 30.4 30.4 
Total 50 36.036 13.8932 24.4 84.0 
 
   N Mean Std. Deviation Range P value 
          Minimum Maximum 
 
TGL Underweight 1 312.00 . 312 312  
 
 
 
0.185  
  Normal 31 227.71 100.394 76 458 
  Overweight 18 291.39 147.025 110 553 
  Total 50 252.32 121.190 76 553 
TC Underweight 1 168.00 . 168 168  
 
 
 
0.718  
  Normal 31 175.77 44.134 110 254 
  Overweight 18 188.83 72.399 131 439 
  Total 50 180.32 55.262 110 439 
HDL Underweight 1 42.00 . 42 42  
 
 
 
0.554  
  Normal 31 42.26 6.298 24 58 
  Overweight 18 44.06 4.108 38 51 
  Total 50 42.90 5.560 24 58 
LDL Underweight 1 63.600 . 63.6 63.6  
 
 
 
0.911 
  Normal 31 87.974 44.8676 15.4 178.2 
  Overweight 18 86.500 71.1788 24.0 328.0 
  Total 50 86.956 54.7916 15.4 328.0 
VLDL Underweight 1 62.400 . 62.4 62.4  
 
 
 
0.185 
  Normal 31 45.542 20.0788 15.2 91.6 
  Overweight 18 58.278 29.4050 22.0 110.6 
  Total 50 50.464 24.2379 15.2 110.6 
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  There is no significance in the correlation of BMI with dyslipidemia in 
either cases or controls The P value of these correlations are well above 0.05 
which signifies that there is no correlation between BMI and dyslipidemia in 
case and control. 
Gender VS Dyslipidemia 
For controls, 
 Sex N Mean Std. Deviation P value 
TGL Male 19 180.11 59.091 
0.995 
 
   
Female 31 180.23 76.070 
TC Male 19 181.05 28.066 
0.314 
 
   
Female 31 173.03 26.395 
HDL Male 19 40.00 2.925 
0.166 
 
   
Female 31 41.19 2.903 
LDL Male 19 105.032 32.2544 
0.343 
 
   
Female 31 95.794 33.5882 
VLDL Male 19 36.021 11.8182 
0.995 
 
   
Female 31 36.045 15.2140 
 There is no significance in the correlation of various parameters of lipid 
profile with that of sex among the control population 
For cases, 
 Sex N Mean Std. Deviation P- value 
TGL Male 21 225.24 104.282 
0.181    
Female 29 271.93 130.330 
TC Male 21 180.90 44.208 
0.950    
Female 29 179.90 62.832 
HDL Male 21 40.95 6.756 
0.034*    
Female 29 44.31 4.072 
LDL Male 21 94.905 38.7801 
0.388 
   29 81.200 64.0140 
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Female 
VLDL Male 21 45.048 20.8565 
0.181    
Female 29 54.386 26.0661 
 All except HDL has no correlation with gender among the case 
population. HDL cholesterol has a significant correlation (P – Value -0.034 i.e., 
<0.05) with the gender among the cases but not among the controls.  
 
Gender Vs. CD4 count 
 Sex N Mean Std. Deviation P- value 
CD4 Count Male 21 296.71 211.409 
0.07    
Female 29 401.76 197.204 
 Correlation between the CD4 count and Gender is not significant in the 
case population 
 
Gender Vs. BMI, 
For controls,  
 Sex N Mean Std. Deviation P- value 
BMI Male 19 23.737 3.0339 
0.164    
Female 31 24.968 2.9607 
 BMI has no correlation with the gender among the controls. 
For cases, 
 Sex N Mean Std. Deviation P-Value 
BMI Male 21 22.941 2.3901 
<0.001*    
Female 29 25.657 2.3473 
 BMI has very high significant correlation with the gender among the case 
population. 
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CD4 count Vs. BMI, 
   Level of BMI Total 
P- value 
    Underweight Normal Overweight   
CD4 Count Up to 199 Count 0 9 3 12 
0.529 
  200-499 Count 1 17 9 27 
  500 and above Count 0 5 6 11 
Total Count 1 31 18 50 
 
BMI  N Mean Std. Deviation Range 
P- value 
 CD4 count       Minimum Maximum 
Up to 199 12 23.828 2.2501 18.6 26.4  
 
 
 
0.538 
200-499 27 24.594 2.5642 17.6 28.9 
500 and 
above 
11 25.079 3.4983 18.9 29.6 
Total 50 24.517 2.7044 17.6 29.6 
 From the above chart, it is made clear that there is no significant 
correlation between CD4 count and BMI. 
CD4 Vs Duration of illness 
CD4 count 
N Mean Std. Deviation Range 
P-value 
      Minimum Maximum 
Up to 199 12 3.75 1.658 1 6 0.821 
200-499 27 3.54 1.704 1 8 
500 and above 11 3.91 1.868 1 7 
Total 50 3.67 1.701 1 8 
 There is no significant association between CD4 count and Duration of 
illness. 
 
Sensitivity/ specificity/ PPV/ NPV of lipid profile for predicting CD4 count 
< (or) ≥200 
Lipid Profile Sensitivity Specificity PPV NPV 
TGL 18.4 83.3 77.8 24.4 
TC 76.3 41.7 80.6 35.7 
HDL 13.2 66.7 55.6 19.5 
LDL 63.2 33.3 75 22.2 
VLDL 18.4 83.3 77.8 24.4 
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From the above chart, it is very clear that TGL, HDL-cholesterol and 
VLDL has a good Specificity and Positive Predictive Value, whereas Total 
cholesterol and LDL cholesterol has good sensitivity and Positive Predictive 
Value. All parameters in lipid profile have very poor negative predictive value. 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
TGL TC HDL LDL VLDL
Sensitivity
Specificity
PPV
NPV
86 
 
Discussion 
This study included data on 50 HIV positive patients and 50 HIV 
negative controls that were matched in age and gender parameters. HIV positive 
patients ,has shown in this study, has a variety of lipid abnormalities including  
elevation of TGL, total cholesterol and reduced level of HDL and LDL 
compared with HIV negative controls but were not significant. Higher level of 
serum TGL was also recorded among HIV positive patients, though this is not 
significant. The level of TGL, TC, HDL and LDL meet the criteria for 
dyslipidemia as defined by the National Cholesterol Education Program Adult 
treatment Panel III(NCEP-ATP III), with mean serum level of greater than 
150mg/dl, 200mg/dl, lesser than 40mg/dl(m) or 50mg/dl(F)  and greater than 
100mg% respectively. Even though the mean LDL was significantly lower than 
control, it did not reach dyslipidemic level. The finding of low HDL in 
treatment naïve patients was slightly lower than the Nutrition for Healthy 
Living (NFHL) control in our study.  In a study based in US, HIV patients who 
are not yet started on HAART have an adjusted OR of 2.7 for low HDL 
compared with general population. This is equally supported by recent study in 
Spain. This finding of low HDL is also similar to results obtained among 
diabetics, diabetics and hypertensive patients. 
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Low HDL is a very well recognised risk factor for poor/adverse 
cardiovascular outcomes and this has also been shown to be true in HIV 
infected individuals, irrespective of other associated risk factors. 
In this study, we found no significant association between mean values of 
lipid parameters, BMI and CD4 count. 
In Many studies, Hypocholesterolemia has been reported in HIV 
infection. In this study Cholesterol is higher in HIV positive patients than 
control but it is not that significant. However, male patients with HIV had an 
elevated level of Total Cholesterol compared with females. This finding is 
supported by the findings of Shor-Posner et al, where occurrence of 
hypercholesterolemia with or without hypertriglyceridemia was found in male 
patients with early infection with HIV -1. Reduced level of cholesterol has been 
demonstrated in early HIV infection, AIDS and some other infections. 
Relatively low cholesterol has been found to be negatively related to Tumor 
Necrosis Factor-alpha, but the mechanisms are not yet clear. 
The reason for lack of association between lipid parameters in HIV 
positive patients and the immune status may be related to the close similarity in 
the CD4 count as most patients are in the CD4 count range 200 –499 cell/mm3. 
Despite this, it has been demonstrated that the reduction in HDL in HIV 
infection persist along all ranges of CD4 levels from the beginning of infection. 
Elevated TG was shown to have positive correlation with interferon alpha, 
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advanced / opportunistic infection when immunity is markedly reduced and 
delayed clearance due to reduced lipoprotein lipase activity. 
Tuberculosis is a common infection in HIV/AIDS patients with a 
prevalence of 12.7% in Ile Ife, and 28.1% in Ibadan. With co infection, there is 
a synergism between the two infections leading to progression of the two 
diseases and ultimately death, if not treated. As revealed in a study done in 
African country, HIV patients co infected with TB had a significantly higher 
mean LDL compared with HIV positive patients who were not co- infected. 
This may indicate an exaggerated state caused by HIV/TB co infection. This 
needs further study to show that there is a prevalence of dyslipidemia in PLHA 
co-infected with Tuberculosis. 
Despite these limitations, our findings indicate that HIV infected 
individuals have a host of variations in their lipid profiles compared with HIV 
negative control in our environment. Low HDL, reaching the dyslipidemic 
range, low LDL and high TGL were found compared with controls. This 
derangement in the lipid profile among Patient living with HIV/AIDS can lead 
to increased adverse vascular event 
BODY MASS INDEX: 
In our BMI has sensitivity 80%, specificity 54% ,accuracy 64%, PPV 
57%and NPV 76% in predicting CD4 count < 200 cells/µL. 
Caroline Costello, MPH, Kenrad E. Nelson, MD, Predictors of 
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LowCD4Count in Resource-Limited Settings .In this study BMI< 18.5 kg/ m² 
has specificity of 95.6% and sensitivity of 13.4% in predicting CD4 count < 200 
cells/µL. 
In our study BMI is more sensitive but less specific when comparing 
with above study in predicting CD4 count < 200 cells/µL. Normal BMI is more 
prevalent in our study population, which in turn decrease the specificity. The 
BMI is normal in our study because most of our patients are in WHO staging II 
and III. 
BMI <18.5kg/m
2
 is more common in stage III and IV when CD4 count is 
<200 cells/ µL .Thus it is useful in predicting CD4 count <200 cells/µL 
AGE 
The mean age of patients in control was 48+11 and the mean age in cases 
was 50+9. There was no statistical significance found between Age and 
dyslipidaemia in both the groups. 
 
SEX DISTRIBUTION 
In our study the prevalence of dyslipidaemia was found to be more 
among females than males in both the groups. But there was no statistically 
significant correlation found between gender and dyslipidaemia. 
There are no studies available to suggest the correlation of Age / Gender 
with dyslipidaemia in HIV – infected patients. 
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TOTAL CHOLESTEROL 
Majority of the patients in our study were found to have normal 
Cholesterol levels in both the groups. Only 20% of patients in control and 28% 
of patients in case population were documented to have high Cholesterol levels 
i.e., more than 200mg%. 
In our study, only 12.0% of patients among cases were found to have 
Cholesterol level > 240mg% whereas in DAD study, the prevalence of 
Cholesterol > 240mg/dl among persons living with HIV/AIDS was 27% 
 Present 
Study 
DAD Study Galli et al 
Prevalence of Cholesterol 
>240mg/dl 
12.0% 27.0% 10% 
HDL CHOLESTEROL 
Majority of patients in our study were found to have normal HDL-C 
levels only 38% of patients among case population and 34% among control 
population were documented to have HDL-C <40mg/dl. 
Hypertriglyceridemia in association with Low HDL-C was commonly 
observed in HIV infected patients before the initiation of HAART 
In DAD study, the prevalence of HDL-C <35mg/dl among HIV infected 
persons was 27.1%. 
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 Present Study DAD Study 
Prevalence of HDL-C < 40mg/dl 16%  
Prevalence of HDL-C < 35mg/dl  27.1% 
 
TRIGLYCERIDES 
Majority of patients in our study were found to have high Triglyceride 
levels in both the groups (62% among controls & 82% among cases) 
In our study, the prevalence of Triglycerides > 200mg/dl were 20.0% 
among control and 60.0% among cases whereas Galli et al, observed that the 
prevalence of TGL> 200mg/dl was 23% in patients  
 Present Study Galli et al 
Prevalence of Triglycerides >200mg/dl 
in HIV infected patients 60% 23% 
Hypertriglyceridemia in association with Low HDL-C was commonly 
observed in HIV – infected persons before the HAART. In our study also, 20% 
of patients among Group 1 found to have elevated TG level >200mg/dl before 
starting HAART. 
Both hypertriglyceridemia and hypocholesterolemia are associated with 
progressive HIV disease. These abnormalities may be a non-specific response 
to chronic infection as indicated by the well-documented relationship between 
Triglycerides concentration and levels of inflammatory cytokines. 
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DYSLIPIDAEMIA 
There was no major or significant alterations in TGL, Total Cholesterol& 
LDL-C levels observed in both the groups, whereas HDL-Cholesterol level, was 
found to have a significant difference between male and female gender. 
In our study, Dyslipidaemia was defined as alteration in any one of the 
three parameters namely Total Cholesterol, Triglyceride and HDL-c alone or 
combination of these abnormalities. 
In our study, there was no statistical significance observed between CD4 
count and dyslipidaemia. But there was a significant correlation between CD4 
count and WHO group. 
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LIMITATIONS OF THE STUDY 
1. Sample size was small so further studies with bigger sample size has to 
be done to further verify the results. 
2. Our study has been done among the population attending Kilpauk 
medical college hospital OPD and there can be a bias in selecting such a 
group of population, so this study has to be done among the general 
population or it has been done at multiple centres and meta-analysis of 
those studies can provide a significant conclusion of this issue among 
patient living with HIV/AIDS. 
3. WHO clinical staging in our cases were done on presumed clinical basis 
and some basic laboratory investigations, so some of the patients may be 
wrongly staged/ categorised. 
 
 
 
 
 
 
 
94 
 
CONCLUSION 
1. The prevalence of dyslipidemia in our study is as follows 
a. Good number of patients had a ‗high risk‘ triglyceride range 
b. ‗Very high risk‘ cholesterol level is significantly higher among 
cases 
c. PLHA had significantly lower level of LDL 
d. HDL level was low particularly among female cases 
2. In our study, majority of the HIV infected population had a CD4 count in 
the range of 200- 499 (54%), where as 24% had CD4 count more than 
500 and 22% had CD4 count less than 200. 
3. There is no significant correlation between the CD4 count and the Levels 
of various parameters of lipid profiles 
4. Apart from the intended correlation, we also attempted to correlate 
various other parameters and we came to a conclusion that  
a) WHO categories correlates with CD4 count i.e., as the staging 
increases, CD4 count decreases. 
b) Gender and HDL correlates well in our study population 
Although the CD4 count is used as ―gold standard‖ test, WHO staging 
can be used as a surrogate marker for CD4 count <200 cells/µL to initiate ART 
in resource limited settings. Lipid profile can never replace CD4 count in areas 
where appropriate facilities are not available. 
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List of abbreviations used 
AHA – American Heart Association 
AIDS – Acquired Immune Deficiency Syndrome 
Apo C3/ Apo E – Apoprotein C3/ Apoprotein E 
ART – Anti Retroviral Therapy 
ATP – Adult Treatment Panel 
BMI – Body Mass Index 
BMI – Body Mass Index 
CAD – Coronary Artery Disease 
cART – Combined AntiRetroviral Therapy 
CCR/CXCR – Cysteine-Cysteine Receptor/ Cysteine-x-Cysteine Receptor 
CD – cluster differentiation 
CDC – Centre for Disease Control 
CHF – Congestive Heart Failure 
CHO – cholesterol 
CMV –CytoMegalo Virus 
CT – Computer Tomography 
DNA – Deoxyribo Nucleic Acid 
ECG – Electrocardiogram 
EIA – Enzyme Immuno Assay 
ELISA – Enzyme Linked ImmunoSorbent Assay 
ESR – Erythrocyte Sedimentation Rate 
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FDB – familial defective apolipoprotein B 
FH – familial hypercholesterolemia  
gp – Glycoprotein 
HAART – Highly Active Antiretroviral Therapy 
HDL-C – High Density Lipoprotein Cholesterol 
HIV – Human Immunosuppression Virus 
HSV – Herpes Simplex Virus 
HTLV – Human T-Lymphotropic Virus 
IDL – Intermediate Density Lipoprotein 
IRIS – Immune Reconstitution Inflammatory Syndrome 
IVIg – Intra Venous Immunoglobulin 
LDL-C – Low Density Lipoprotein Cholesterol 
MI – Myocardial Infarction 
MRI – Magnetic Resonance Imaging 
NCEP – National Cholesterol Education Programme 
PCSK-9 - Proprotein Convertase Subtilisin/Kexin Type 9 
PLHA – Patient Living with HIV/ AIDS 
RNA – Ribo Nucleic Acid 
STD – Sexually Transmitted Disease 
TC – Total Cholesterol 
TGL – Triglycerides 
TLC – Total Leucocyte Count 
110 
 
TSH – Thyroid Stimulating Hormone 
UNAIDS – United Nation Programme on HIV/AIDS 
URAI – Unprotective Receptive Anal Intercourse 
WHO – World Health Organisation 
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 PROFORMA 
H/o Drug use 
H/o viral hepatitis, Jaundice, Liver disease 
H/o alcohol consumption /drinking pattern 
NAME:                                                                                                 UNIT 
NO.:               I.P.NO.: 
AGE/SEX:                           
OCCUPATION:                                                                                   DATE 
OF ADMISSION: 
ADDRESS:                                       DATE OF DISCHARGE: 
 
 
                                                                                                                                                      
CONTACT NO: 
COMPLAINTS: 
HISTORY: 
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PAST HISTORY: 
 Duration of HIV 
 Complaint for which he/she was done HIV screening 
   Diabetes/ Hypertension/ Dyslipidemia/ CAD/ CKD  
FAMILY HISTORY: Dyslipidemia 
PERSONAL HISTORY: Chewing Tobacco/ Smoking/ Alcohol/ Drug Abuse 
TREATMENT HISTROY (DRUGS): 
GENERAL PHYSICAL EXAMINATION: 
HT:    WT:     BMI: 
 
 
VITALS: 
BP:   PR:   RR: 
 
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
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P/A: 
CNS: 
Others  
 
INVESTIGATIONS:  
LIPID PROFILE 
Triglycerides Total 
Cholesterol 
HDL- C LDL-C VLDL-C 
     
 
RENAL PROFILE 
Random sugar Urea Creatinine 
   
 
Complete Hemogram 
TC DC ESR HB Platelet count 
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CD4 cell count 
CD4  
 
ECG all leads 
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